Innovative cell therapies for a healthier world
O futuro da medicina regenerativa
Heart failure affects 26 million people worldwide
The costs associated with Heart Failure exceed 100 billion dollars a year
Did you know?
context
Rett syndrome is a genetic disease that has no definitive treatment
Rett Syndrome is a disease of the autistic spectrum
What we do
LizarBio Therapeutics is a startup that develops cell therapies based on pluripotent stem cells. We are currently focused on developing therapies for patients with heart and neurological problems. More specifically, congestive heart failure (CHF) and Rett syndrome. We believe that cell therapy is the future of regenerative medicine.
Pipeline
Currently, LizarBio Therapeutics is focused on solving problems in two specific diseases, namely: Heart Failure through the use of cardiac cells and Rett Syndrome with the use of healthy astrocytes, both of the cells produced in the laboratory. In the future, we plan to expand our operations to other areas such as ophthalmology, endocrinology and etc., always producing authentic human cells on a scale.
Disease
Cell Type
Research
POC Pre-
Clinica
Clinica
Ind enablign tests
PH 1/2
Heart failure
Cardiomyocytes
Today
Q4/2023
Q1/2026
Q4/2027
Rett Syndrome
Astrocytes
Today
Q4/2023
Q4/2027
Publications
To Scale or not to scale? That’s the question!
Last week we shared a small but meaning thing that shows how much work is necessary...
Are all cells made equal? (by Marcos Valadares)
In the general public, there is a sense that there only exist 2 general cell types:...
It’s the COGs*, stupid! (by Marcos Valadares)
Ref: Image modified from: https://workful.com/blog/cost-goods-sold/ Let me explain the title, first! Apparently, the first time this...
The manufacturing trap (by Marcos Valadares)
Previously, we have discussed here that cell therapies hold great promisses but are currently limited in...
Cell Therapy: hope or hype?
Ref: https://handling-solutions.eppendorf.com/cell-handling/stem-cells/growth-surfaces/detailview-growth-surfaces/news/scaling-up-stem-cell-culture/ Here is an interesting fact: you are made of roughly 37.2 trillion of cells...
Lab grown cells or meat? Tell me more...
We have come a long way since American embryologist Ross Granville Harrison developed the first techniques...
Scientific Publications
2021 - Cell Therapy Moving in the Right Direction
Read more2017 - Cardiomyocyte oxidants production may signal to T. cruzi intracellular development
Read more2018 - Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease
Read more2020 - Long-term single-cell passaging of human iPSC fully supports pluripotency and high-efficient trilineage differentiation capacity
Read more2021 - In Situ Maturated Early-Stage Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Improve Cardiac Function by Enhancing Segmental Contraction in Infarcted Rats
Read more2021 - Non-permissive SARS-CoV-2 infection in human neurospheres
Read moreLizarBio Therapeutics Team
Marcos Valadares
CEO
Diogo Biagi
CSO
Estela Cruvinel
Principal Investigator
Rafael Dariolli
Principal Investigator (Pre-Clinical Tests)
Sofia Ramos
Cell Culture Coordinator
Antônio Ribeiro
Pre-Clinical Researcher
Julliana Carvalho
Pre-Clinical Researcher
Sirlene Rodrigues
Junior Researcher
Renato Leite
Admin Staff
Contact us through the channels below, or fill out the form:
Antônio Ribeiro
Pre-Clinical Researcher
Antonio is a biologist from Paulista University with a master and doctor degree in human genetics from the Bioscience Institute, University of São Paulo. He has experience in histology and molecular biology, having worked with muscle regeneration in animal models
